Predictive Value of Sex Chromosome Loss in Sex-Mismatched Stem Cell Transplantation
Understanding Sex Chromosome Loss in Stem Cell Transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a primary curative therapy for various hematologic malignancies, including leukemias and lymphomas. In many clinical scenarios, patients receive grafts from donors of the opposite sex, known as sex-mismatched transplants. One curious phenomenon observed during post-transplant monitoring is sex chromosome loss (SCL). SCL refers to the disappearance of the Y chromosome in male cells or an X chromosome in female cells. While SCL is known to occur naturally as part of the aging process in healthy individuals, its appearance after a high-stakes procedure like a stem cell transplant has long puzzled clinicians. Does it represent a benign physiological change, or is it a harbinger of disease recurrence? A recent retrospective study published in Bone Marrow Transplantation aims to clarify the clinical significance of SCL and provides a potential threshold for identifying patients at high risk for treatment failure.
The Mechanics of Sex-Mismatched Transplantation
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.